Hartfalen: epidemiologie, risicofactoren en toekomst

RIVM Rapport 260401006
(2011). Pro-B-type natriuretic peptide(1-108) circulates in the general
community: plasma determinants and detection of left ventricular
dysfunction. J Am Coll Cardiol 57, 1386-95.
Macintyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath
A, Pell JP, Mcmurray JJ (2000). Evidence of improving prognosis in heart
failure: trends in case fatality in 66 547 patients hospitalized between 1986
and 1995. Circulation 102, 1126-31.
Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK,
Baugh JA, Mcdonald KM (2009). Natural history of markers of collagen
turnover in patients with early diastolic dysfunction and impact of
eplerenone. J Am Coll Cardiol 54, 1674-82.
Mann DL, Bogaev R, Buckberg GD (2010). Cardiac remodelling and myocardial
recovery: lost in translation? Eur J Heart Fail 12, 789-96.
Marantz PR, Alderman MH, Tobin JN (1988). Diagnostic heterogeneity in clinical
trials for congestive heart failure. Ann Intern Med 109, 55-61.
Marín-García J (2008). Aging and the Heart. New York: Springer.
Marron BJ, Pelliccia A. (2006) The heart of trained athletes. Cardiac remodeling
and the risks of sports, including sudden death. Circulation 114: 1633-41.
Martos R, Baugh J, Ledwidge M, O'loughlin C, Murphy NF, Conlon C, Patle A,
Donnelly SC, Mcdonald K (2009). Diagnosis of heart failure with preserved
ejection fraction: improved accuracy with the use of markers of collagen
turnover. Eur J Heart Fail 11, 191-7.
McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD
(2002). Confirmation of a heart failure epidemic: findings from the Resource
Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol
39, 60-9.
McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, Mcmurray JJ,
Dargie HJ (1997). Symptomatic and asymptomatic left-ventricular systolic
dysfunction in an urban population. Lancet 350, 829-33.
McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer
RJ, Burnett JC, Jr. (2010). The prognostic value of N-terminal pro-B-type
natriuretic peptide for death and cardiovascular events in healthy normal and
stage A/B heart failure subjects. J Am Coll Cardiol 55, 2140-7.
McMullen JR, Jennings GL (2007). Differences between pathological and
physiological cardiac hypertrophy: novel therapeutic strategies to treat heart
failure. Clin Exp Pharmacol Physiol 34(4): 255-262.
McMurray J, Mcdonagh T, Morrison CE, Dargie HJ (1993). Trends in
hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 14, 1158-
62.
Mehta PA, Dubrey SW, Mcintyre HF, Walker DM, Hardman SM, Sutton GC,
Mcdonagh TA, Cowie MR (2009). Improving survival in the six months after
diagnosis of heart failure in the past decade: population-based data from the
UK. Heart.
Milani RV, Drazner MH, Lavie CJ, Morin DP, Ventura HO (2011). Progression
from concentric left ventricular hypertrophy and normal ejection fraction to
left ventricular dysfunction. Am J Cardiol 108, 992-6.
Milder IEJ, Veldwijk J, Verschuren WMM, Blokstra A, Uiters AH, Bemelmans WJE.
Gecombineerde leefstijlbegeleiding bij overgewicht. Om hoeveel mensen gaat
het in Nederland? Bilthoven: RIVM, 2010.
Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA,
Levy D, Benjamin EJ (2010). Arterial stiffness and cardiovascular events: the
Framingham Heart Study. Circulation 121, 505-11.
Morgan S, Smith H, Simpson I, Liddiard GS, Raphael H, Pickering RM, Mant D
(1999). Prevalence and clinical characteristics of left ventricular dysfunction
Pagina 107 van 122